Optimal Timing of Zoster Vaccine After Zoster Illness

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the optimal timing of zoster vaccination to induce both higher cell-mediated immunity and humoral immunity in adult patients aged over 50 with history of zoster within 5 years.

Clinical Trial Description

Zoster vaccination is recommended by FDA for adults aged 60 years or older, and is approved for people aged 50 through 59 years old. For patients who had shingles, there is no specific length of time they must wait before receiving shingles vaccine. It is generally recommended that patients should wait for 6 to 12 months after recovery.

The investigators plan to make scientific recommendation for optimal timing of zoster vaccine after zoster illness by comparing immune response between two groups (vaccination at 6 months to 2 years after shingles vs. 2 to 5 years after shingles). Primary outcome is ELISPOT response at week 6 after vaccination. Secondary outcome is gpELISA titer at week 6 after vaccination.

All the patients will be asked if they have any contraindications for zoster vaccine by a physician before vaccination. And they will be monitored for any adverse reaction of the vaccination after 6 weeks (visiting the hospital). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02704572
Study type	Interventional
Source	Seoul National University Hospital
Contact
Status	Completed
Phase	N/A
Start date	March 2016
Completion date	August 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01132729` - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions	N/A
Completed	`NCT01132716` - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions	N/A
Completed	`NCT04099706` - Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT	N/A
Completed	`NCT04540081` - Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer	N/A
Completed	`NCT01527370` - Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)	Phase 3
Completed	`NCT00534248` - Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)	Phase 3
Completed	`NCT01262300` - Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents	Phase 1
Completed	`NCT00576108` - A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)	Phase 2
Completed	`NCT00109122` - Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)	Phase 2
Completed	`NCT04047979` - Systems Biology of Zoster Vaccine	Phase 2
Active, not recruiting	`NCT05871541` - A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine	Phase 1
Completed	`NCT02114333` - Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds	Phase 1
Completed	`NCT00900783` - A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster	Phase 2
Completed	`NCT01600079` - ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)
Active, not recruiting	`NCT02444936` - ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors	Phase 4
Recruiting	`NCT05554068` - Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients	Phase 2
Recruiting	`NCT06238726` - Nudging Patients to Increase Shingles Vaccination	N/A
Completed	`NCT00300222` - Study of NGX-4010 for the Treatment of Postherpetic Neuralgia	Phase 3
Terminated	`NCT02412917` - A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia	Phase 3
Completed	`NCT00115310` - Study of NGX-4010 for the Treatment of Postherpetic Neuralgia	Phase 3